Leiden, the Netherlands Saturday, March 22, 2025, 12:00 Hrs [IST] ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Pharming Group (PHAR – Research Report) today and set a price target of ...

Motorists are alerted to heavy traffic along parts of the North Luzon Expressway (NLEx) after an 18-wheeler truck struck the ...

Phishing is quite a broad term, therefore organisations and individuals could benefit from breaking down the phrase and ...

Hereditary angioedema is a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of ...

The National Institute for Health and Care Excellence (NICE) has recommended Pharming’s Joenja (leniolisib) to treat patients with the ultra-rare immune disease, activated phosphoinositide 3-kinase ...

Pharming Group (NASDAQ:PHAR – Get Free Report) had its price target hoisted by research analysts at Oppenheimer from $30.00 ...

Pharming Group (PHGUF) reports a 21% increase in full-year revenue, strategic Abliva acquisition, and positive financial outlook for 2025.

The European market has recently experienced a slight downturn, with the pan-European STOXX Europe 600 Index ending lower amid ongoing uncertainty about U.S. trade policy. Despite these challenges, ...

Full Year 2024 Results Key Financial Results Revenue: US$297.2m (up 21% from FY 2023).

Discover key insights from Pharming Group's Q4 2024 earnings call. Explore strong revenue growth, RUCONEST & Joenja drivers, and 2025 strategic priorities.

The company reported fourth-quarter sales growth of 9.8% year-on-year to $839.535 million, beating the analyst consensus estimate of $807.590 million. Adjusted EPS of $1.27 beat the consensus estimate ...